- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05148611
Application Registration Study of ILE in Patients With Acute Poisoning (ILE)
2. desember 2021 oppdatert av: Peking Union Medical College Hospital
In this study, the investigators aimed to study the effect of ILE in the treatment of acute fat-soluble substance poisoning,to further clarify the relevant mechanism of ILE in the treatment of fat-soluble drug poisoning,to standardize the relevant procedures of ILE detoxification treatment and further explore the adverse reactions and coping strategies of ILE treatment.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Detaljert beskrivelse
Fat-soluble drugs refer to drugs that are insoluble in water but soluble in fats and organic solvents such as carbon tetrachloride, glycerol, oils and other organic solvents.
They can fuse with the phospholipid bilayer of cell membranes, are easily absorbed, and are easier to pass compared to water-soluble drugs.
It is metabolized by the liver, and the metabolites are excreted by the kidneys, so it has a high clinical use rate.
However, in recent years, due to the improper use of fat-soluble drugs by patients, fat-soluble benzodiazepines sedative and hypnotic drugs, fat-soluble calcium channel blockers and β-blocker drugs, fat-soluble tricyclic drugs have often occurred.
Poisoning such as antidepressants poses a serious threat to the lives of patients.In addition, organophosphorus pesticides (fat-soluble) have a high usage rate in China.
Severe organophosphorus poisoning can cause multiple organ damages, and delays in treatment can cause disability or even death.
Clinical treatment is mainly based on routine gastric lavage and oxygen inhalation.
Treatment is the mainstay, combined with medical drugs, hemodialysis, hemoperfusion, etc., and has achieved certain curative effects, but the mortality rate is still high, so it is of great significance to explore safer and more effective treatment methods.Intravenous lipid emulsion (ILE) was originally used to treat overdose of local anesthetics such as bupivacaine, and later also used to treat a variety of other lipophilic drug poisonings.
The research on the treatment of ILE is still in the preliminary stage and relatively limited.
A systematic review of fat emulsions for the treatment of acute poisoning found that the overall quality of the studies supporting this treatment is low or very low, but the included case reports indicate that fat emulsions are effective against verapamil, beta blockers, and certain Tricyclic antidepressants, bupivacaine, chlorpromazine, and certain antiarrhythmic drugs (eg, flecainide) poisoned patients have certain benefits.
ILE may help treat patients who are hemodynamically unstable due to poisoning by these drugs.In view of the fact that the research on the treatment of ILE still needs to be further improved and related adverse reactions need to be further explored related countermeasures, the investigators plan to launch a registration research program related to the application of fat emulsion.
Studietype
Observasjonsmessig
Registrering (Forventet)
500
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: yi li, Medical PhD
- Telefonnummer: 15098750165
- E-post: qmbb719@163.com
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
N/A
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
According to the indications of ILE in the treatment of poisoning in clinical toxicology, the research objects are divided into the following categories:
- Calcium channel blocker poisoning
- Beta blocker drug poisoning
- Tricyclic antidepressant poisoning
- Organophosphorus (fat-soluble) pesticide poisoning, such as: chlorpyrifos, profenofos, diazinon, fenthion, phosphaphos, quinalphos, butylpyrimidin, thiazophos, omethoate, dimethoate Methionine, triazophos, thiomethionine, ethion, sulfoxiphos, imiphos, fosfoxcarb, pyrifoxaphos, hydrocarbophos, phorate, methyl parathion, parasulfur Phosphorus, dichlorvos, pyridoxine, etc.
- Local anesthetic poisoning
- Poisoning by other fat-soluble substances
Beskrivelse
Inclusion Criteria:
- Diagnosed as acute fat-soluble drug and organophosphorus (fat-soluble) pesticide poisoning;
- Conventional treatment is ineffective, especially for patients with circulatory failure, such as ventricular arrhythmia, shock, cardiac arrest, etc., who need intravenous fat emulsion treatment;
- Those who are not allergic to fat milk;
- Sign informed consent.
Exclusion Criteria:
- Mergers with insufficiency of important organs;
- Patients with malignant tumors;
- Severe mental disorder affects the treatment;
- Those with incomplete clinical data.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
mortality rate
Tidsramme: 24 hours
|
Patient mortality within 24 hours
|
24 hours
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Circulatory system
Tidsramme: 24 hours
|
Circulation stabilization time: including blood pressure stabilization time, disappearance time of malignant arrhythmia, etc.
|
24 hours
|
mortality rate
Tidsramme: 1 week and 28 days
|
1 week and 28 days patient mortality
|
1 week and 28 days
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
30. november 2021
Primær fullføring (Forventet)
30. desember 2021
Studiet fullført (Forventet)
1. oktober 2025
Datoer for studieregistrering
Først innsendt
1. november 2021
Først innsendt som oppfylte QC-kriteriene
2. desember 2021
Først lagt ut (Faktiske)
8. desember 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
8. desember 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
2. desember 2021
Sist bekreftet
1. september 2021
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ZS-3185D
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .